Biogen Inc. (NASDAQ:BIIB) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference operator today. At this time, I’d like to welcome everyone to the Biogen Fourth Quarter and Full Year 2024 Earnings Call and Business Update.
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street forecasts fourth-quarter adjusted EPS of $3.35 and sales of $2.40 billion, while fiscal year 2024 adjusted EPS is expected to be $16.
Biogen (BIIB) Q4 2024 Earnings Call Transcript
At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I would now like to turn the conference over to Mr.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.95 per share a year ago. These figures are adjusted for non-recurring items.
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by the company’s cost-cutting efforts.
Earnings call transcript: Biogen Q4 2024 EPS beats estimates, stock drops
Biogen Inc. (NASDAQ:BIIB), currently valued at $19.15 billion by market capitalization, reported its earnings for the fourth quarter of 2024, surpassing analysts' expectations with a non-GAAP diluted earnings per share (EPS) of $3.
Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
Biotech company Biogen (NASDAQ:BIIB) reported in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP profit of $3.44 per share was 2.3% above analysts’ consensus estimates. Is now the time to buy Biogen?
Hosted on MSN31m
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc. GILD gained following the earnings beat and upbeat guidance for 2025, ...
Piper Sandler Remains a Hold on Biogen (BIIB)
Piper Sandler analyst David Amsellem maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $138.00. The ...
Biogen Analysts Lower Their Forecasts After Q4 Results
The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales ...
Biogen (NASDAQ:BIIB) Stock Price Down 6.8% Following Analyst Downgrade
Biogen Inc. (NASDAQ:BIIB – Get Free Report) traded down 6.8% during trading on Wednesday after Bank Of America (Bofa) lowered ...
Biogen (BIIB) Gets a Buy from Mizuho Securities
Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.
Yahoo Finance4d
Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts
In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed ...
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...
Nasdaq14d
March 14th Options Now Available For Biogen (BIIB)
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...